

CHAPTER 9

Kidney Failure in Aotearoa New Zealand

ANZDATA gratefully acknowledges the patients and their whānau/families and the clinicians who provided data, and the contributions of the Aotearoa New Zealand Working Group and the National Renal Transplant Service

CONTENTS

Summary and Highlights	3
Suggested Citation	3
Kidney Replacement Therapy in Aotear New Zealand	roa 4
Incidence of Kidney Replacement Therapy (KRT)	4
Primary Cause of Kidney Disease	5
Children and Young Adults	5
Age	6
Prevalence of Kidney Replacement Therapy	7
Dialysis	8
Transplantation	9
Late Referral to Nephrology Services	9
Ethnicity and Kidney Replacement Therapy in Aotearoa New Zealand	10
New Patients	10
Primary Kidney Disease	13
Incidence Rates	13

Prevalent Patients	15
Diabetes	16
Incidence and Prevalence per Populat	tion 17
Transplantation	18
Transplant Survival	21
Dialysis	22
Timing of Dialysis Initiation	23
Vascular Access	24
Patient Flow	26
Cause of Death	27
Late Referral to Nephrology Services	28
References	29

SUMMARY AND HIGHLIGHTS

This chapter presents information about the rates of people receiving kidney replacement therapy (KRT) for kidney failure in the form of dialysis or transplantation in Aotearoa New Zealand. Population statistics from estimates provided by Statistics New Zealand are used to calculate disease and treatment rates¹. Ethnicity population data are projections produced by Statistics New Zealand according to assumptions agreed to by the New Zealand Ministry of Health; these include data from the 2018 census and incorporate additional information gained from the post-enumeration survey.

This report highlights persistent ethnic disparities in kidney health, treatment access, and outcomes, calling for greater attention to these inequities in care. Also, the growing KRT population and the increasing number of facility-based haemodialysis are putting significant strain on already limited renal service resources, including both facility capacity and staffing.

In 2023, 725 people began KRT, amounting to 138 per million population (pmp). There is an increasing per population trend with the highest incidence of KRT among the 65-74 age group (374 pmp). By the end of 2023, 5,572 people were receiving KRT, with a higher prevalence of dialysis (611 pmp) over transplants (453 pmp).

Diabetic kidney disease remained the leading cause (49.5%) of end stage kidney disease in New Zealand, significantly higher than Australia, especially among Māori (66%) and Pacific People (68%), while glomerular disease was more common among non-Māori non-Pacific populations.

65% of received KRT in the form of haemodialysis in hospitals or satellite unit with a number now exceeding 2000 patients in 2023 exerting ongoing pressure on dialysis facility capacity and staff resources. There is a decrease in home-based dialysis therapy over the last 5 years.

Significant disparities exist in KRT incidence based on ethnicity. Pacific Peoples had the highest rate (478 pmp), followed by Māori (205 pmp), and non-Māori non-Pacific groups (82 pmp). In addition, Māori and Pacific Peoples had much lower rates of pre-emptive transplants compared to other ethnic groups. Māori and Pacific Peoples also have a 3-5 times higher mortality rate compared to non-Māori non-Pacific patients.

Māori and Pacific People are less likely to receive kidney transplant and patient survival post-transplant was also lower for Māori (85%) compared to non-Māori non-Pacific (91%) after five years.

SUGGESTED CITATION

T Sun, C Davies, E Au, S Bateman, J Chen, P Clayton, K Hurst, F Kholmurodova, D Lee, H McCarthy, S McDonald, W Mulley, M Roberts, B Solomon, G Irish. 47th Report, Chapter 9: Kidney Failure in Aotearoa New Zealand. Australia and New Zealand Dialysis and Transplant Registry, Adelaide, Australia. 2024. Available at: <u>http://www.anzdata.org.au</u>

KIDNEY REPLACEMENT THERAPY IN AOTEAROA NEW ZEALAND

INCIDENCE OF KIDNEY REPLACEMENT THERAPY (KRT)

In 2023, 725 adults and children started kidney replacement therapy (KRT) in Aotearoa New Zealand, equivalent to 138 per million of population (pmp) (Figure 9.1 and Table 9.1). The proportion of the Aotearoa New Zealand population commencing KRT is similar to that of Australia (138 versus 129 pmp in 2023).

Figure 9.1

Incidence of Kidney Replacement Therapy - Aotearoa New Zealand 1994-2023




Table 9.1Number (pmp) who Commenced Kidney Replacement Therapy in Aotearoa New Zealand, 2019-2023

	2019	2020	2021	2022	2023
Total	659 (132)	716 (141)	725 (142)	703 (137)	725 (138)
Pre-Emptive Transplant	35 (7)	44 (9)	39 (8)	23 (4)	25 (5)
Haemodialysis	384 (77)	404 (79)	439 (86)	445 (87)	489 (93)
Peritoneal Dialysis	240 (48)	268 (53)	247 (48)	235 (46)	211 (40)

Trends in the proportion of patients starting KRT by treatment modality are in Figure 9.2.


Figure 9.2 Trends in Modality at Start of Kidney Replacement Therapy - Aotearoa New Zealand 2014-2023 100 80 Percent of new patients 60 40 20 Haemodialysis Peritoneal Dialysis Kidney Transplant 0 2014 2016 2018 2020 2022 2024

PRIMARY CAUSE OF KIDNEY DISEASE

Figure 9.3 shows the primary cause of kidney failure for all patients commencing KRT in 2023.

Figure 9.3

Primary Cause of Kidney Disease of New Patients Commencing Kidney Replacement Therapy, 2023




CHILDREN AND YOUNG ADULTS

In 2023, 28 patients in the 0-24 age group commenced kidney replacement therapy (17 pmp) in Aotearoa New Zealand. The incidence rate of KRT among young patients has ranged between 11 and 18 pmp from 2019-2023. The incidence rate of KRT is variable due to the low numbers of patients commencing KRT in this age group.

Of the 28 younger patients commencing KRT in Aotearoa New Zealand in 2023, 2 (7%) patients received a pre-emptive transplant, 8 (29%) patients commenced with peritoneal dialysis, and 18 (64%) patients commenced with haemodialysis (Figure 9.4).

Figure 9.4 Children and Young Adults (0-24 years) Commencing KRT - Aotearoa New Zealand 2014-2023




AGE

Kidney replacement therapy incidence rates vary widely by age group and modality (Figures 9.5 and 9.6).

In 2023, the highest incidence of kidney replacement therapy in Aotearoa New Zealand is among people in the 65-74 age group (374 pmp). Children, young adults, and adults 85 years and older have the lowest rates of kidney replacement therapy.

Figure 9.5 Incidence of Kidney Replacement Therapy by Age Group - Aotearoa New Zealand, 2014-2023

Figure 9.6 Incidence of KRT by Age Group and Modality -Per Million Population, Aotearoa New Zealand 2023







Figure 9.7 shows the mean age of incident kidney replacement therapy patients in Aotearoa New Zealand over the last 10 years.





PREVALENCE OF KIDNEY REPLACEMENT THERAPY

There were 5572 people (1064 pmp) receiving KRT in Aotearoa New Zealand at the end of 2023 (Figures 9.8-9.9 and Table 9.2). Overall Aotearoa New Zealand has a higher prevalence (611 pmp) of patients on dialysis than patients with a kidney transplant (453 pmp).

Figure 9.8 Prevalence of Dialysis and Transplantation - Aotearoa New Zealand 1994-2023





Table 9.2Prevalence of Kidney Replacement Therapy (pmp) in Aotearoa New Zealand 2019-2023

	2019	2020	2021	2022	2023
Total	4940 (992)	5165 (1015)	5389 (1054)	5429 (1061)	5572 (1064)
Transplant	2100 (422)	2194 (431)	2279 (446)	2315 (452)	2374 (453)
Dialysis	2840 (570)	2971 (584)	3110 (608)	3114 (609)	3198 (611)
% Dialysis	57%	58%	58%	57%	57%





DIALYSIS


In 2023, 35% of the 3198 Aotearoa New Zealand dialysis patients had home-based dialysis (peritoneal dialysis, community house haemodialysis or home haemodialysis).

15% of the dialysis population were treated with automated peritoneal dialysis, 8% with continuous ambulatory peritoneal dialysis, and 12% with home haemodialysis.

Figure 9.10 shows trends in the method and location of dialysis in Aotearoa New Zealand over 2019-2023.

The Registry recognised that previous definitions for dialysis location did not accurately reflect the care delivery for all patients in Aotearoa New Zealand and in 2020 introduced new data definitions to capture patients receiving community-based therapy. Due to the small number of Community House Dialysis patients reported to the Registry in 2023 (39 patients across Aotearoa New Zealand) this data has been combined with Home Haemodialysis numbers for reporting purposes in this report.





HD: Haemodialysis, SAT: Satellite, HOSP: Hospital, APD: Automated Peritoneal Dialysis, CAPD: Continuous Ambulatory Peritoneal Dialysis

65% of dialysis patients had haemodialysis in a satellite unit (20%) or a hospital unit (45%).

Figure 9.11 shows the home (including community house) and facility-based dialysis trends in Aotearoa New Zealand over 2019-2023.





Figure 9.11 Home and Facility Based Dialysis - Aotearoa New Zealand, 2019-2023

TRANSPLANTATION

In 2023, 175 patients (33 pmp) received a kidney transplant (Figure 9.12).


Figure 9.12 New Kidney Transplants in Actearoa New Zealand 2019-2023



LATE REFERRAL TO NEPHROLOGY SERVICES

Figure 9.13 shows the rate of late referrals (defined as the first assessment by a specialist nephrologist within 3 months of commencing dialysis) in Aotearoa New Zealand over time by age group. Late referrals represented 13% of all patients who commenced kidney replacement therapy in 2023.

Figure 9.13 Late Referral Rates by Age Group - Aotearoa New Zealand 2014 - 2023



ETHNICITY AND KIDNEY REPLACEMENT THERAPY IN AOTEAROA NEW ZEALAND


NEW PATIENTS

There are marked and persistent inequities in the incidence and prevalence of kidney failure and the kidney replacement therapies provided based on ethnicity in Aotearoa New Zealand.

The incidence of kidney replacement therapy is markedly higher among Pacific Peoples (478 pmp) and Māori (205 pmp) patients, compared with Non-Māori, non-Pacific patients (82 pmp) (Figure 9.14).


Please note that collection of ethnicity data in ANZDATA has evolved to align with the Australian Bureau of Statistics Australian Standard Classification of Cultural and Ethnic Groups² and data collection now allows a patient to nominate more than one ethnicity group. However, consultation regarding ethnicity data reporting is ongoing, and reporting guidelines are not finalised at publication. As a result, ethnicity data throughout this report includes only the first nominated ethnicity category entered for each patient. Future reporting will aim to report more accurately on patients with more than one ethnicity.

Figure 9.14 Incidence of KRT by Ethnicity - Aotearoa New Zealand 2019-2023




The initial therapy for patients starting KRT by ethnicity is in Figure 9.15. Overall, 7% of non-Māori and non-Pacific patients had a pre-emptive kidney transplant, while 1% of incident Māori patients received pre-emptive kidney transplants and 0% of Pacific Peoples patients.





The percentage of pre-emptive kidney transplants has continued to be markedly lower among Māori and Pacific Peoples patients compared to non-Māori and non-Pacific patients (Figure 9.16).





A total of 185 patients identifying as Māori, and 219 patients identifying as Pacific Peoples, commenced treatment for kidney failure in 2023, representing 26% and 30%, respectively, of all patients starting kidney replacement therapy. This inequity in the incidence of kidney failure treated with kidney replacement therapy in Māori and Pacific Peoples is persistent. The rate of haemodialysis commencement for non-Māori and non-Pacific patients was 3-fold lower than for Māori and 8-fold lower than for Pacific Peoples. Māori and Pacific Peoples were more likely to commence haemodialysis (HD) than peritoneal dialysis (PD) compared with non-Māori and non-Pacific patients (Figure 9.17). Only 2 Māori and 0 Pasifka patients had a pre-emptive kidney transplant in 2023. In the last 5 years, 15 Māori and 6 Pacific Peoples patients have received a pre-emptive kidney transplant compared with 143 non-Māori and non-Pacific patients (a 10-fold difference for Māori and 24-fold difference for Pacific Peoples).

Table 9.3


New Patients (pmp) Aotearoa New Zealand 2019-2023

Year	Modality	Non-Māori, non-Pacific	Māori	Pacific Peoples	Total
	Haemodialysis	135 (36)	136 (163)	111 (265)	382 (77)
2019	Peritoneal Dialysis	124 (33)	74 (89)	41 (98)	239 (48)
	Pre-emptive Transplant	30 (8)	1 (1)	4 (10)	35 (7)
	Haemodialysis	139 (37)	128 (150)	128 (297)	395 (78)
2020	Peritoneal Dialysis	148 (39)	80 (94)	39 (91)	267 (52)
	Pre-emptive Transplant	36 (9)	5 (6)	1 (2)	42 (8)
	Haemodialysis	170 (45)	127 (145)	139 (316)	436 (85)
2021	Peritoneal Dialysis	136 (36)	57 (65)	54 (123)	247 (48)
	Pre-emptive Transplant	33 (9)	6 (7)	0 (0)	39 (8)
	Haemodialysis	196 (52)	113 (127)	136 (303)	445 (87)
2022	Peritoneal Dialysis	121 (32)	76 (85)	37 (82)	234 (46)
	Pre-emptive Transplant	21 (6)	1 (1)	1 (2)	23 (4)
2023	Haemodialysis	184 (47)	123 (136)	179 (391)	486 (93)
	Peritoneal Dialysis	111 (29)	60 (66)	40 (87)	211 (40)
	Pre-emptive Transplant	23 (6)	2 (2)	0 (0)	25 (5)

22 excluded due to unreported ethnicity.

Figure 9.17

Percentage of New Patients Commencing on Haemodialysis - Aotearoa New Zealand



PRIMARY KIDNEY DISEASE

The primary kidney diseases of incident patients in Aotearoa New Zealand during 2019-2023 are in Table 9.4. Māori and Pacific Peoples peoples have a substantially higher rate of diabetic kidney disease than non-Māori, non-Pacific patients.

Table 9.4

Primary Kidney Disease of New Patients in Aotearoa New Zealand 2019-2023


Primary Kidney Disease	Non-Māori, non-Pacific	Māori	Pacific Peoples
Diabetic kidney disease	464 (29%)	652 (66%)	619 (68%)
Glomerular disease	415 (26%)	125 (13%)	137 (15%)
Hypertension / Renal vascular disease	222 (14%)	60 (6%)	48 (5%)
Familial / hereditary kidney diseases	164 (10%)	20 (2%)	13 (1%)
Tubulointerstitial disease	156 (10%)	58 (6%)	28 (3%)
Other systemic diseases affecting the kidney	46 (3%)	12 (1%)	7 (1%)
Miscellaneous kidney disorders	133 (8%)	56 (6%)	55 (6%)
Not reported	7 (<1%)	6 (1%)	3 (<1%)
Total	1607	989	910

22 excluded due to unreported ethnicity.

INCIDENCE RATES

Overall, the incidence rates of kidney failure for Māori and Pacific Peoples patients are markedly and persistently higher than those for non-Māori and non-Pacific patients. This inequity is likely confounded and underestimated by the age distributions of each population with Māori and Pacific Peoples populations being considerably younger. Over the last ten years the incidence rates for Pacific Peoples and Māori patients have diverged due to an increase in the incidence in Pacific Peoples patients, but not in Māori patients.


Figure 9.18 Unadjusted Incident KRT Rate - Aotearoa New Zealand



The incidence rates for KRT by ethnicity are in Figure 9.18. The relative rate differs with age, see Figure 9.19.

Figure 9.19

Relative Incidence Rate of Treated Kidney Failure for Māori and Pacific Peoples Patients, compared with non-Māori, non-Pacific patients - Aotearoa New Zealand 2019-2023



Among Māori and Pacific Peoples peoples, inequities in the incidence of kidney failure occur as early as ages 15 to 24 years and are evident across all age groups (Figure 9.19).

Age specific trends in kidney replacement therapy are shown in Figures 9.20.1-9.20.3, by patient ethnicity; note that the Y axis scales vary.

Figure 9.20.1 Age-specific Incidence Rates of Treated Kidney Failure




Figure 9.20.2 Age-specific Incidence Rates of Treated Kidney Failure - Māori, Aotearoa New Zealand





Figure 9.20.3

Age-specific Incidence Rates of Treated Kidney Failure - Pacific Peoples, Aotearoa New Zealand



PREVALENT PATIENTS

The number of prevalent patients with treated kidney failure by treatment modality and ethnicity is in Table 9.5 and Figure 9.21. The proportion of patients undergoing haemodialysis at home in each ethnic group is in Figure 9.22.

Table 9.5

Prevalent Patients by Ethnicity and Treatment Modality Aotearoa New Zealand 2019-2023

Year	Modality	Non-Māori, non-Pacific	Māori	Pacific Peoples
	HD	679 (25%)	673 (57%)	662 (63%)
0010	% HD at home*	26%	20%	15%
2019	PD^	398 (15%)	247 (21%)	173 (17%)
	Transplant	1632 (60%)	252 (22%)	211 (20%)
	HD	678 (24%)	706 (57%)	728 (66%)
0000	% HD at home*	24%	18%	13%
2020	PD^	426 (15%)	255 (21%)	160 (14%)
	Transplant	1701 (61%)	267 (22%)	219 (20%)
	HD	756 (26%)	749 (60%)	783 (66%)
2021	% HD at home*	22%	16%	13%
2021	PD^	419 (14%)	225 (18%)	162 (14%)
	Transplant	1746 (60%)	283 (23%)	241 (20%)
	HD	802 (27%)	719 (58%)	815 (68%)
	% HD at home*	21%	16%	13%
2022	PD^	395 (13%)	218 (18%)	149 (12%)
	Transplant	1769 (60%)	296 (24%)	242 (20%)
	HD	860 (28%)	715 (58%)	867 (68%)
2023	% HD at home*	20%	15%	12%
	PD^	384 (13%)	206 (17%)	149 (12%)
	Transplant	1798 (59%)	312 (25%)	254 (20%)

*Includes Community House HD

^Includes Hybrid Dialysis

114 excluded due to unreported ethnicity.

Figure 9.21.1 Prevalent Patients by Modality -Aotearoa New Zealand - Māori




Figure 9.21.3 Prevalent Patients by Modality -Aotearoa New Zealand - Non-Māori, non-Pacific




Figure 9.21.2 Prevalent Patients by Modality -Aotearoa New Zealand - Pacific Peoples





Figure 9.22 Prevalent Haemodialysis at Home^{*} (% of all HD[^]) by Ethnicity - Aotearoa New Zealand




DIABETES

The percentage of prevalent KRT patients with diabetes as a comorbidity is shown in Figure 9.23 by ethnicity and treatment modality.

Figure 9.23 Diabetes as a Comorbidity in Prevalent Patients -

Aotearoa New Zealand, 2014-2023



INCIDENCE AND PREVALENCE PER POPULATION

Figures 9.24 to 9.29 show trends in the incidence and prevalence of kidney failure treatment overall and by modality. Of note is the increasing prevalence of transplantation amongst Māori and Pacific Peoples patients (Figure 9.28). Figure 9.29 shows mortality by ethnicity.

Figure 9.24





Figure 9.26 Prevalent Haemodialysis[^] Patients -Aotearoa New Zealand








Figure 9.25 Incidence of New Transplants - Aotearoa New Zealand




Figure 9.27 Prevalent Peritoneal Dialysis[^] Patients -Aotearoa New Zealand





Figure 9.29 Deaths of KRT Patients - Aotearoa New Zealand



TRANSPLANTATION

In Aotearoa New Zealand, the proportion of Māori and Pacific Peoples patients who receive a kidney transplant is very low. However, the transplant rate per million population is high due to the prevalence of kidney failure in these populations (Table 9.6). Information on the donor source is in Figure 9.30 and trends are in Figure 9.31 (note that the Y axis scales vary).

Table 9.6

Number of Transplant Recipients (pmp) by Donor Type and Ethnicity Aotearoa New Zealand 2014-2023

Year	Donor Type	Non-Māori, _ non-Pacific	Māori	Pacific Peoples
	Deceased Donor	44 (13)	13 (17)	9 (24)
2014	Living Donor	52 (15)	12 (16)	7 (19)
	Total	96 (28)	25 (33)	16 (43)
	Deceased Donor	44 (13)	13 (17)	16 (42)
2015	Living Donor	54 (16)	15 (20)	5 (13)
	Total	98 (28)	28 (36)	21 (56)
	Deceased Donor	58 (16)	13 (17)	19 (49)
2016	Living Donor	57 (16)	13 (17)	12 (31)
	Total	115 (32)	26 (33)	31 (80)
	Deceased Donor	71 (20)	17 (21)	30 (75)
2017	Living Donor	52 (14)	6 (7)	11 (28)
	Total	123 (34)	23 (29)	41 (103)
	Deceased Donor	65 (18)	15 (18)	18 (44)
2018	Living Donor	59 (16)	14 (17)	11 (27)
	Total	124 (34)	29 (36)	29 (71)
	Deceased Donor	83 (22)	24 (29)	23 (55)
2019	Living Donor	73 (20)	11 (13)	7 (17)
	Total	156 (42)	35 (42)	30 (72)
	Deceased Donor	60 (16)	23 (27)	17 (39)
2020	Living Donor	68 (18)	14 (16)	3 (7)
	Total	128 (34)	37 (43)	20 (46)
	Deceased Donor	55 (14)	23 (26)	23 (52)
2021	Living Donor	62 (16)	14 (16)	8 (18)
	Total	117 (31)	37 (42)	31 (70)
2022	Deceased Donor	53 (14)	28 (31)	23 (51)
	Living Donor	53 (14)	13 (15)	4 (9)
	Total	106 (28)	41 (46)	27 (60)
	Deceased Donor	58 (15)	19 (21)	22 (48)
2023	Living Donor	52 (13)	14 (15)	8 (17)
	Total	110 (28)	33 (37)	30 (66)

7 excluded due to unreported ethnicity.

Figure 9.30 Donor Type by Ethnicity - Aotearoa New Zealand 2014-2023




Figure 9.31 Donor Type by Ethnicity and Year - Aotearoa New Zealand






Figure 9.32 shows the cumulative incidence curve of primary transplant after starting KRT (utilising competing risk techniques to account for the effect of the competing risk of death). Figure 9.33 shows the cumulative incidence curves of primary transplant after starting KRT by era.

Figure 9.32 Time to Primary Transplant from KRT Start - Aotearoa New Zealand Incident KRT Patients 2014-2023








TRANSPLANT SURVIVAL

Graft and patient survival for kidney transplant recipients in Aotearoa New Zealand, calculated by the Kaplan-Meier method, are shown in Figures 9.34-9.35.


There is a small difference in patient survival after kidney transplantation from a deceased donor between Māori and non-Māori, non-Pacific recipients, which is apparent from 6 months after transplantation. At 5 years post-transplant, 85% of Māori recipients, 89% of Pacific Peoples recipients, and 91% of non-Māori, non-Pacific recipients were alive 5 years after kidney transplantation from a deceased donor (Figure 9.34).

Figure 9.34 Patient Survival, Recipients of Primary Deceased Donor Grafts - Aotearoa New Zealand 2014-2023




Over the first 5 years after a kidney transplant from a deceased donor, some kidney transplants are lost, either through the transplant failing or the patient dying with a functioning kidney. Over time, there are increasing proportions of Māori and Pacific Peoples recipients who experienced graft loss compared with non-Māori, non-Pacific persons. The proportion of functioning kidney transplants at 5 years post-transplant was 78% for Māori and 82% for Pacific Peoples recipients, compared with 86% for non-Māori, non-Pacific persons (Figure 9.35).

Figure 9.35 Graft Survival, Recipients of Primary Deceased Donor Grafts - Aotearoa New Zealand 2014-2023



Cumulative incidence curves (utilising competing risk techniques to account for the effects of both components of graft failure, i.e. graft failure and death with a functioning graft) are shown for transplant outcomes by ethnicity in Figure 9.36.

Figure 9.36 Transplant Outcomes, Aotearoa New Zealand - Primary Deceased Donor Kidney-only Transplants 2014-2023




DIALYSIS

The distribution of dialysis modality is shown graphically in Figure 9.37. Māori and Pacific Peoples patients have higher use of facility dialysis as the principal modality of care and lower use of the home-based modalities.

Figure 9.37

Dialysis Modality End 2023 - Aotearoa New Zealand, by Ethnicity



Half of the people who started dialysis over 2014-2023 were alive 5 years later (Figure 9.38). Non-Māori non-Pacific and Māori patients experienced similar survival over 5 years after starting dialysis, with Pacific Peoples patients having better survival. Observed differences in survival between populations may reflect different age distributions and access to competing treatments (transplantation), which may have impacted mortality estimates.





Figure 9.38 Patient Survival, Incident Dialysis Patients -Aotearoa New Zealand 2014-2023

TIMING OF DIALYSIS INITIATION

The level of kidney function at which dialysis is commenced (based on estimated Glomerular Filtration Rate (eGFR)) is shown in Figure 9.39 by patient ethnicity.

Figure 9.38

Patient Survival, Incident Dialysis Patients - Aotearoa New Zealand 2014-2023



VASCULAR ACCESS

Incident Vascular Access

Incident vascular access data by patient ethnicity are documented in Table 9.7, and prevalent data in Table 9.8.

Table 9.7

Incident Vascular Access Aotearoa New Zealand 2019-2023

Year	Vascular access	Non-Māori, non-Pacific	Māori	Pacific Peoples
	AVF	33 (24%)	28 (21%)	20 (18%)
	AVG	2 (1%)	0 (0%)	1 (1%)
2019	CVC	100 (74%)	107 (79%)	90 (81%)
	Not reported	0 (0%)	1 (1%)	0 (0%)
	AVF	31 (22%)	22 (17%)	33 (26%)
	AVG	0 (0%)	0 (0%)	0 (0%)
2020	CVC	106 (76%)	106 (83%)	95 (74%)
	Not reported	2 (1%)	0 (0%)	0 (0%)
	AVF	41 (24%)	22 (17%)	32 (23%)
2004	AVG	1 (1%)	0 (0%)	0 (0%)
2021	CVC	127 (75%)	105 (83%)	103 (74%)
	Not reported	1 (1%)	0 (0%)	4 (3%)
	AVF	44 (22%)	17 (15%)	26 (19%)
	AVG	1 (1%)	0 (0%)	0 (0%)
2022	CVC	150 (77%)	95 (84%)	110 (81%)
	Not reported	1 (1%)	1 (1%)	0 (0%)
2023	AVF	24 (13%)	14 (11%)	29 (16%)
	AVG	2 (1%)	1 (1%)	0 (0%)
	CVC	158 (86%)	108 (88%)	150 (84%)
	Not reported	0 (0%)	O (O%)	0 (0%)

AVF: Arteriovenous Fistula, AVG: Arteriovenous Graft, CVC: Central Venous Catheter

17 excluded due to unreported ethnicity.

Prevalent Vascular Access

Vascular access for prevalent haemodialysis patients are shown in Table 9.8 by patient ethnicity.

Table 9.8 Prevalent Vascular Access^ Aotearoa New Zealand 2019-2023

Year	Vascular access	Non-Māori, non-Pacific	Māori	Pacific Peoples
	AVF	390 (57%)	422 (63%)	436 (66%)
	AVG	16 (2%)	18 (3%)	5 (1%)
2019	CVC	247 (36%)	213 (32%)	193 (29%)
	Not reported	26 (4%)	20 (3%)	28 (4%)
	AVF	376 (55%)	411 (58%)	440 (60%)
	AVG	11 (2%)	17 (2%)	13 (2%)
2020	CVC	263 (39%)	251 (36%)	263 (36%)
	Not reported	28 (4%)	27 (4%)	12 (2%)
	AVF	388 (51%)	449 (60%)	443 (57%)
	AVG	11 (1%)	11 (1%)	10 (1%)
2021	CVC	319 (42%)	267 (36%)	309 (39%)
	Not reported	38 (5%)	22 (3%)	21 (3%)
	AVF	380 (47%)	397 (55%)	436 (53%)
	AVG	17 (2%)	8 (1%)	9 (1%)
2022	CVC	362 (45%)	287 (40%)	347 (43%)
	Not reported	43 (5%)	27 (4%)	23 (3%)
	AVF	378 (44%)	373 (52%)	448 (52%)
	AVG	18 (2%)	8 (1%)	15 (2%)
2023	CVC	430 (50%)	319 (45%)	388 (45%)
	Not reported	38 (4%)	16 (2%)	16 (2%)

^Includes Hybrid Dialysis

44 excluded due to unreported ethnicity.

PATIENT FLOW

Table 9.9 shows the overall patient flow in Aotearoa New Zealand by ethnicity. Notably, mortality for Māori and Pacific Peoples patients is 3 to 5-fold higher per million of the population than that of non-Māori, non-Pacific patients.

Table 9.9

Patient Flow (pmp) Aotearoa New Zealand 2019-2023

Year	Event	Non-Māori, non-Pacific	Māori	Pacific Peoples
	New patients	289 (78)	211 (253)	156 (373)
	New transplants	156 (42)	35 (42)	30 (72)
	Pre-emptive transplants	30 (8)	1 (1)	4 (10)
2019	Prevalent dialysis	1077 (289)	920 (1104)	835 (1995)
	Prevalent transplants	1632 (438)	252 (302)	211 (504)
	Total prevalence	2709 (727)	1172 (1406)	1046 (2499)
	Deaths	243 (65)	200 (240)	109 (260)
	New patients	323 (85)	213 (249)	168 (390)
	New transplants	127 (33)	37 (43)	20 (46)
	Pre-emptive transplants	36 (9)	5 (6)	1 (2)
2020	Prevalent dialysis	1104 (290)	961 (1125)	888 (2062)
	Prevalent transplants	1701 (447)	267 (312)	219 (508)
	Total prevalence	2805 (737)	1228 (1437)	1107 (2570)
	Deaths	219 (58)	161 (188)	105 (244)
	New patients	339 (89)	190 (217)	193 (439)
	New transplants	117 (31)	37 (42)	31 (70)
	Pre-emptive transplants	33 (9)	6 (7)	0 (0)
2021	Prevalent dialysis	1175 (310)	974 (1113)	945 (2147)
	Prevalent transplants	1746 (460)	283 (323)	241 (548)
	Total prevalence	2921 (769)	1257 (1437)	1186 (2695)
	Deaths	217 (57)	157 (179)	119 (270)
	New patients	338 (89)	190 (213)	174 (388)
	New transplants	106 (28)	41 (46)	27 (60)
	Pre-emptive transplants	21 (6)	1 (1)	1 (2)
2022	Prevalent dialysis	1197 (317)	937 (1052)	964 (2147)
	Prevalent transplants	1769 (468)	296 (332)	242 (539)
	Total prevalence	2966 (785)	1233 (1384)	1206 (2686)
	Deaths	289 (77)	213 (239)	155 (345)
	New patients	318 (82)	185 (205)	219 (478)
	New transplants	110 (28)	33 (37)	30 (66)
	Pre-emptive transplants	23 (6)	2 (2)	0 (0)
2023	Prevalent dialysis	1244 (321)	921 (1019)	1016 (2219)
	Prevalent transplants	1798 (464)	312 (345)	254 (555)
	Total prevalence	3042 (785)	1233 (1364)	1270 (2774)
	Deaths	236 (61)	190 (210)	152 (332)

Patients with unreported ethnicity are excluded.

CAUSE OF DEATH

The causes of death in 2023 are in Figure 9.40 and Table 9.10, categorised by ethnicity and modality at the time of death.

Differences between ethnicities are likely to reflect, at least in part, the different age distributions of these populations.

Figure 9.40 Cause of Death by Modality and Ethnicity -Deaths Occurring During 2023, Aotearoa New Zealand




Table 9.10Cause of Death by Modality and Ethnicity, Aotearoa New Zealand 2023

Modality	Cause of death	Non-Māori, non- Pacific	Māori	Pacific Peoples
	Cardiovascular	72 (39%)	98 (54%)	75 (54%)
	Withdrawal	46 (25%)	28 (16%)	14 (10%)
	Cancer	4 (2%)	2 (1%)	2 (1%)
Dialysis	Infection	22 (12%)	21 (12%)	26 (19%)
	Other	27 (15%)	22 (12%)	21 (15%)
	Not reported	12 (7%)	9 (5%)	1 (1%)
	Total	183	180	139
	Cardiovascular	16 (30%)	3 (30%)	6 (46%)
	Withdrawal	3 (6%)	0 (0%)	0 (0%)
	Cancer	12 (23%)	1 (10%)	1 (8%)
Transplant	Infection	12 (23%)	2 (20%)	5 (38%)
	Other	10 (19%)	4 (40%)	1 (8%)
	Not reported	0 (0%)	0 (0%)	0 (0%)
	Total	53	10	13

2 excluded due to unreported ethnicity.

LATE REFERRAL TO NEPHROLOGY SERVICES

Late referral rates (defined as the first assessment by a specialist nephrologist within 3 months of commencing dialysis) by ethnicity in Aotearoa New Zealand are in Figure 9.41 and Table 9.11.

Figure 9.41 Late Referral Rates by Ethnicity - Aotearoa New Zealand 2019 - 2023




Table 9.11Percentage of Late Referral by Ethnicity Actearoa New Zealand 2019-2023

Year	Non-Māori, non-Pacific	Māori	Pacific Peoples
2019	13%	15%	14%
2020	7%	15%	8%
2021	10%	12%	10%
2022	13%	15%	9%
2023	10%	13%	19%

REFERENCES

- 1. This work is based on/includes Stats NZ's data which are licensed by Stats NZ for re-use under the Creative Commons Attribution 4.0 International licence. Stats NZ, 2023, Estimated Resident Population by Age and Sex (1991+) (Annual-Jun), NZ Infoshare, viewed 14 Dec 2023, http://infoshare.stats.govt.nz/
- 2. Australian Bureau of Statistics, 2019, Australian Standard Classification of Cultural and Ethnic Groups (ASCCEG), December 2019, viewed 23 Oct 2020, <u>https://www.abs.gov.au/AUSSTATS/abs@.nsf/</u> Lookup/1249.0Main+Features12019?OpenDocument



CHAPTER 9

Kidney Failure in Aotearoa New Zealand